By Mill Chart
Last update: Jun 3, 2025
EXELIXIS INC (NASDAQ:EXEL) has been identified as a strong growth stock with a favorable technical setup by our stock screener. The company demonstrates solid growth fundamentals while also presenting a promising technical pattern. Below, we examine why EXEL stands out in both areas.
EXELIXIS earns a high fundamental rating of 8/10, supported by strong growth, profitability, and financial health. Key highlights include:
The technical analysis report assigns EXEL a 10/10 rating, with a setup score of 8/10, indicating a consolidation phase with breakout potential:
Stocks with strong fundamentals and bullish technical patterns often present compelling opportunities. EXELIXIS fits this profile, combining accelerating earnings growth with a favorable chart structure.
For a deeper dive, review the full fundamental report and technical analysis.
Our Strong Growth Stocks with Good Technical Setup screener lists more stocks meeting these criteria and is updated daily.
This is not investment advice. The observations here are based on data available at the time of writing. Always conduct your own research before making investment decisions.
42.88
-0.16 (-0.37%)
Find more stocks in the Stock Screener
EXELIXIS INC (NASDAQ:EXEL) shows strong growth fundamentals and a bullish technical setup, making it a stock worth watching for investors seeking growth opportunities.
EXELIXIS INC (NASDAQ:EXEL) shows strong earnings growth, expanding margins, and solid cash flow, making it a standout for growth investors following Louis Navellier’s strategy.
EXELIXIS INC (NASDAQ:EXEL) offers strong growth, solid profitability, and an attractive valuation, making it a compelling choice for investors seeking affordable growth stocks in the biotech sector.
EXELIXIS INC (NASDAQ:EXEL) is an undervalued biotech stock with strong profitability, financial health, and growth potential, making it a candidate for value investors.
EXELIXIS INC (NASDAQ:EXEL) meets Minervini’s Trend Template with strong technicals and high growth momentum, making it a standout in biotech. Review its full technical and fundamental strengths before considering an investment.